Protected: Abliva’s clinical trials

Abliva discovers and develops medicines for the treatment of mitochondrial diseases. Lead candidate, KL1333 - a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. The global FALCON study is now recruiting.

This content is password protected. To view it please enter your password below: